1. Home
  2. XBIO vs HKPD Comparison

XBIO vs HKPD Comparison

Compare XBIO & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$2.80

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

HKPD

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

N/A

Current Price

$0.67

Market Cap

6.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XBIO
HKPD
Founded
N/A
2016
Country
United States
Hong Kong
Employees
2
27
Industry
Biotechnology: Pharmaceutical Preparations
Other Pharmaceuticals
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
6.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XBIO
HKPD
Price
$2.80
$0.67
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.1K
17.2K
Earning Date
03-13-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.81
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.90
$0.58
52 Week High
$13.93
$2.74

Technical Indicators

Market Signals
Indicator
XBIO
HKPD
Relative Strength Index (RSI) 51.08 53.64
Support Level $2.64 $0.67
Resistance Level $3.12 $0.70
Average True Range (ATR) 0.26 0.05
MACD -0.02 0.01
Stochastic Oscillator 32.71 91.94

Price Performance

Historical Comparison
XBIO
HKPD

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.

Share on Social Networks: